Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riliprubart Long-term Safety in Cold Agglutinin Disease
NCT04802057Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- IgG Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of riliprubart in cold agglutinin disease (CAD), sponsored by Sanofi. Primary endpoint: Number of participants with treatment-emergent adverse events. Started Mar 2021; status: terminated.
02
Drugs
riliprubart
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT04802057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802057.